Odonate Therapeutics, Inc.
Odonate Therapeutics, Inc. (ODT): 1 pipeline candidate · ~19 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
19.3 months
D/E 0.48 · 0% dilution
Lead: Phase 3
1 candidate
N/A
N/A
A transparent, data-derived signal for Odonate Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$95.7M
Quarterly Burn
$15.1M
Runway
19.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| tesetaxel | Phase 3 |
Frequently asked questions
How many drug candidates are in Odonate Therapeutics, Inc.'s pipeline?
Odonate Therapeutics, Inc. (ODT) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Odonate Therapeutics, Inc.'s lead drug candidate?
Odonate Therapeutics, Inc.'s most advanced tracked candidate is tesetaxel (Phase 3) for Metastatic breast cancer (MBC).
What is Odonate Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Odonate Therapeutics, Inc. has approximately 19.3 months of cash runway.
Who is the CEO of Odonate Therapeutics, Inc.?
Kevin Tang is the chief executive officer of Odonate Therapeutics, Inc. (ODT).
Get the full picture on Odonate Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.